430 reports of this reaction
4.5% of all ALECTINIB HYDROCHLORIDE reports
#5 most reported adverse reaction
CONSTIPATION is the #5 most commonly reported adverse reaction for ALECTINIB HYDROCHLORIDE, manufactured by Genentech, Inc.. There are 430 FDA adverse event reports linking ALECTINIB HYDROCHLORIDE to CONSTIPATION. This represents approximately 4.5% of all 9,588 adverse event reports for this drug.
Patients taking ALECTINIB HYDROCHLORIDE who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is moderately reported among ALECTINIB HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to constipation, the following adverse reactions have been reported for ALECTINIB HYDROCHLORIDE:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 430 FDA reports for ALECTINIB HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 4.5% of all adverse event reports for ALECTINIB HYDROCHLORIDE, making it a notable side effect.
If you experience constipation while taking ALECTINIB HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.